156 related articles for article (PubMed ID: 21393628)
21. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
[TBL] [Abstract][Full Text] [Related]
22. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
[TBL] [Abstract][Full Text] [Related]
23. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
Zhang LL; Pan HX; Wang YX; Guo T; Liu L
Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
[TBL] [Abstract][Full Text] [Related]
24. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
Behbod F; Erwin-Cohen RA; Wang ME; Trawick BW; Qu X; Verani R; Kahan BD; Stepkowski SM; Kirken RA
J Immunol; 2001 Mar; 166(6):3724-32. PubMed ID: 11238613
[TBL] [Abstract][Full Text] [Related]
25. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
26. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
27. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways.
Nagy ZS; Ross JA; Rodriguez G; Bader J; Dimmock J; Kirken RA
FEBS Lett; 2010 Apr; 584(8):1515-20. PubMed ID: 20211620
[TBL] [Abstract][Full Text] [Related]
28. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.
Ruiz-Medina BE; Ross JA; Kirken RA
J Biol Chem; 2015 Aug; 290(34):20972-20983. PubMed ID: 26152718
[TBL] [Abstract][Full Text] [Related]
30. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
Kim BH; Yi EH; Jee JG; Jeong AJ; Sandoval C; Park IC; Baeg GH; Ye SK
J Cell Mol Med; 2020 Jul; 24(13):7427-7438. PubMed ID: 32558259
[TBL] [Abstract][Full Text] [Related]
31. A novel intramolecular negative regulation of mouse Jak3 activity by tyrosine 820.
Sekine Y; Kikkawa K; Witthuhn BA; Kashiwakura JI; Muromoto R; Kitai Y; Fujimuro M; Oritani K; Matsuda T
Int Immunol; 2022 Jun; 34(6):303-312. PubMed ID: 35192696
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
33. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation.
Cohney SJ; Sanden D; Cacalano NA; Yoshimura A; Mui A; Migone TS; Johnston JA
Mol Cell Biol; 1999 Jul; 19(7):4980-8. PubMed ID: 10373548
[TBL] [Abstract][Full Text] [Related]
34. Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
Wilson LJ; Malaviya R; Yang C; Argentieri R; Wang B; Chen X; Murray WV; Cavender D
Bioorg Med Chem Lett; 2009 Jun; 19(12):3333-8. PubMed ID: 19427203
[TBL] [Abstract][Full Text] [Related]
35. Excreted-secreted antigens of Toxoplasma gondii inhibit Foxp3 via IL-2Rγ/JAK3/Stats pathway.
Chen J; Huang C; Zhu D; Chen L; Wang J; Sun X; Hu L; Duan Y
J Cell Biochem; 2018 Dec; 119(12):10176-10185. PubMed ID: 30129110
[TBL] [Abstract][Full Text] [Related]
36. The molecular mechanism of curcumol on inducing cell growth arrest and apoptosis in Jurkat cells, a model of CD4⁺ T cells.
Wang H; Wang Y; Jiang X; Wang Z; Zhong B; Fang Y
Int Immunopharmacol; 2014 Aug; 21(2):375-82. PubMed ID: 24877754
[TBL] [Abstract][Full Text] [Related]
37. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.
Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA
J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068
[TBL] [Abstract][Full Text] [Related]
38. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
[TBL] [Abstract][Full Text] [Related]
39. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
40. A novel indole-3-propanamide exerts its immunosuppressive activity by inhibiting JAK3 in T cells.
Carbonnelle D; Duflos M; Marchand P; Chauvet C; Petit JY; Lang F
J Pharmacol Exp Ther; 2009 Nov; 331(2):710-6. PubMed ID: 19710367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]